LEGN: Legend Biotech to present CARVYKTI and LB2501 data at ASH 2026
Legend Biotech to present 7 ASH 2026 abstracts Dec 12-15 on CARVYKTI CARTITUDE-4 subgroups and LB2501 in vivo CAR-T data.
What this filing says
Legend Biotech said its CARVYKTI and next-generation cell therapy work was accepted for the 2026 American Society of Hematology meeting in December, including new CARTITUDE-4 subgroup analyses and updated first-in-human data for LB2501. The release also repeats CARVYKTI safety figures from the CARTITUDE-1 and CARTITUDE-4 studies, including neurologic toxicities, cytopenias and infections. For a shareholder, this is a scheduled scientific update, not a financial result, and the outcomes presented are still to be seen.
Key figures
- Oral presentations
- two
- Poster presentations
- four
- Patients in CARVYKTI safety data
- 285
- Patients with neurologic toxicities
- 24% (69/285)
- Patients with infections
- 57% (163/285)
- Patients with Grade 5 infections
- 5% (13/285)
Positive for shareholders
- Multiple CARVYKTI abstracts were accepted for a major hematology meeting, with new CARTITUDE-4 analyses on earlier-line use.
- Updated first-in-human data for LB2501, an investigational off-the-shelf in vivo CAR-T therapy, will also be shown.
Negative for shareholders
- Grade 3 or higher cytopenias not resolved by Day 30 occurred in 62% of the 285 patients.
- Neurologic toxicities occurred in 24% of patients, including Grade 3 or higher cases in 7%.
- Patients treated with CARVYKTI had an increased rate of fatal COVID-19 infections compared to the standard therapy arm.
Written by Quantisnow AI from this filing. Not financial advice.
Form 6-K main document
Key terms
- CRS:
- Cytokine release syndrome, an immune reaction that can cause fever and low blood pressure after cell therapy.
- ICANS:
- Immune effector cell-associated neurotoxicity syndrome, a neurological side effect that can follow CAR-T treatment.
- Cytopenias:
- Reductions in blood cell counts, such as platelets, neutrophils or red cells.
- Off-the-shelf:
- Describes a therapy made in advance from donor cells rather than custom-made from each patient's own cells.
FAQ
When will Legend Biotech present its CARVYKTI data at ASH 2026?
The release says the American Society of Hematology Annual Meeting takes place December 12 to 15 in New Orleans, Louisiana.
What is LB2501 and what data will be shown?
The release describes LB2501 as an investigational, off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells, with updated data from its first-in-human trial to be presented.
Historical context for LEGN
Across the 29 sessions after earlier LEGN headlines, the stock closed higher 12 times and lower 17 times, with a median move of 4.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | LEGN | SPY |
|---|---|---|---|
| Nov 4, 2026 | Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026 | +6.0% | +1.7% |
| Oct 27, 2026 | Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results | +5.7% | +0.6% |
| Oct 15, 2026 | Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy | +4.0% | +0.3% |
| Oct 1, 2026 | Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma | -2.9% | +0.2% |
| Sep 25, 2026 | Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion | +0.3% | +0.5% |
| Sep 15, 2026 | Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer | -4.6% | -0.5% |
Keep researching LEGN
- What is Form 6-K?The SEC form foreign private issuers use to furnish material information they publish at home, such as earnings releases and major announcements.
- Form 8-K explainedWhat a Form 8-K is, when it is due, and what each key item number means, from 1.01 material agreements and 2.02 earnings to 4.02 restatements and 5.02 executive changes.
- LEGN insider tradesEvery buy and sale reported by Legend Biotech Corporation officers, directors and large holders.
- LEGN earnings historyPast Legend Biotech Corporation earnings releases, newest first.
- LEGN financial statementsRevenue, profit, cash flow and balance sheet from Legend Biotech Corporation's SEC filings.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2020
Follow LEGN and get a push notification the moment its next story breaks.